Results 101 to 110 of about 40,728 (191)

The Large Ectodomain of APP Prevents APP from being Directly Cleaved by γ-Secretase

open access: yesFrontiers in Bioscience-Landmark
Background: Alzheimer’s disease (AD) is characterized by the deposition of amyloid-β peptide (Aβ) in the brain. Aβ is produced by sequential β- and γ-secretase cleavages of amyloid precursor protein (APP).
Yuan Li   +4 more
doaj   +1 more source

Coordinated and widespread expression of γ-secretase in vivo: evidence for size and molecular heterogeneity

open access: yesNeurobiology of Disease, 2004
γ-Secretase is a high molecular weight protein complex composed of four subunits, namely, presenilin (PS; 1 or 2), nicastrin, anterior pharynx defective-1 (Aph-1; A or B), and presenilin enhancer-2 (Pen-2), and is responsible for the cleavage of a number
Sébastien S. Hébert   +8 more
doaj   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

open access: yesMedComm, Volume 7, Issue 5, May 2026.
The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He   +9 more
wiley   +1 more source

Presenilin-dependent intramembrane cleavage of ephrin-B1

open access: yesMolecular Neurodegeneration, 2006
Background Presenilin-dependent γ-secretase cleavage of several transmembrane proteins, including amyloid-β precursor protein and Notch, mediates the intramembrane proteolysis to liberate their intracellular domains that are involved in cellular ...
Tomita Taisuke   +3 more
doaj   +1 more source

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575 [PDF]

open access: yes, 2009
The γ-secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of γ-secretase prevented formation of new plaques. It has
Monica Garcia-Alloza   +8 more
core   +1 more source

Phosphate‐ and pH‐dependent self‐assembly of recombinant spider silk proteins

open access: yesProtein Science, Volume 35, Issue 5, May 2026.
Abstract The process of molecular self‐assembly is an omnipresent mechanism in nature to generate a variety of efficient and functional hierarchical architectures, and inspires tailored material design and development. Thereby, self‐assembly is based on a controlled interplay and association of monomers into highly ordered structures triggered by ...
Vanessa T. Trossmann   +5 more
wiley   +1 more source

Effect of Notch and PARP Pathways’ Inhibition in Leukemic Cells [PDF]

open access: yes, 2018
Differentiation of blood cells is one of the most complex processes in the body. It is regulated by the action of transcription factors in time and space which creates a specific signaling network.
Antica, Mariastefania   +2 more
core   +2 more sources

Alphafuser: a parsimonious approach to predicting higher‐order protein complexes

open access: yesActa Crystallographica Section D, Volume 82, Issue 5, Page 421-433, May 2026.
Alphafuser is a structure‐prediction pipeline that integrates experimental interaction data with AlphaFold‐based modeling to systematically assemble multiprotein complexes in a computationally efficient manner. By implementing an ipTM‐based pruning algorithm and validating against known structures and experimental assays, Alphafuser enables the ...
Audrey Guillotin   +5 more
wiley   +1 more source

Protein Aggregates and Polyglutamine Tracts In Neurodegenerative Disease [PDF]

open access: yes, 2018
The incidence of neurodegenerative diseases such as Alzheimer\u27s Disease, Parkinson\u27s Disease, Huntington\u27s Disease and other Polyglutamine Diseases is projected to dramatically increase throughout the developed world, and yet the pathology of ...
Mack, John
core   +1 more source

Elranatamab: Mechanism of Action, Clinical, and Translational Science

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy